Trial results

$ZBIO — obexelimab

Zenas BioPharma, Inc. (ZBIO) obexelimab: trial results in Systemic Lupus Erythematosus (SLE), 2026.

Research by Catalyst Intel

The catalyst

"Phase 2 SunStone trial in Systemic Lupus Erythematosus (SLE) topline results expected in 4Q 2026."

— Zenas BioPharma, 8-K filed 2026-10-13 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

ZBIO-OBEXELIMAB-2026

Company

Zenas BioPharma, Inc.

Kind

Trial results

Indication

Systemic Lupus Erythematosus (SLE)

Window

2026-10-01 – 2026-12-31

Status

slate

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.